CERS - Cerus Corp Stock Price, Fair Value and News

1.66USD-0.02 (-1.19%)Market Closed

Market Summary

USD1.66-0.02

Market Closed

-1.19%

CERS Stock Price

View Fullscreen

CERS RSI Chart

CERS Valuation

Market Cap

304.6M

Price/Earnings (Trailing)

-8.12

Price/Sales (Trailing)

1.63

EV/EBITDA

-11.12

Price/Free Cashflow

-6.38

CERS Price/Sales (Trailing)

CERS Profitability

EBT Margin

-19.98%

Return on Equity

-71.28%

Return on Assets

-18.98%

Free Cashflow Yield

-15.68%

CERS Fundamentals

CERS Revenue

Revenue (TTM)

186.8M

CERS Earnings

Earnings (TTM)

-37.5M

Earnings Growth (Yr)

90.54%

Earnings Growth (Qtr)

82.26%

Breaking Down CERS Revenue

Last 30 days

-9.7%

Last 90 days

-6.7%

Trailing 12 Months

-31.7%

How does CERS drawdown profile look like?

CERS Financial Health

Current Ratio

2.14

CERS Investor Care

Shares Dilution (1Y)

2.06%

Diluted EPS (TTM)

-0.21

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	187.9M	187.6M	187.2M	186.8M
2022	0	0	0	188.3M
2021	116.2M	120.6M	126.5M	159.5M
2020	95.0M	96.7M	98.9M	114.2M
2019	0	76.3M	79.0M	135.9M
2018	50.1M	48.3M	44.8M	79.7M
2017	36.6M	36.8M	37.5M	43.6M
2016	34.2M	34.6M	36.7M	37.2M
2015	36.2M	36.5M	34.2M	34.2M
2014	37.8M	36.2M	36.1M	36.4M
2013	37.7M	38.7M	41.0M	39.7M
2012	33.1M	35.6M	36.1M	36.7M
2011	22.1M	23.0M	25.7M	30.6M
2010	0	19.2M	20.4M	21.7M
2009	0	0	0	18.0M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Cerus Corp

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 14, 2024	corash laurence m	sold	-28,352	1.9744	-14,360	chief scientific officer
Mar 14, 2024	greenman william mariner	sold	-128,195	2.0153	-63,611	president and ceo
Mar 14, 2024	jayaraman vivek k	sold	-52,902	1.9744	-26,794	chief operating officer
Mar 14, 2024	benjamin richard j	sold	-35,021	1.9744	-17,738	chief medical officer
Mar 14, 2024	jensen chrystal	sold	-35,191	1.9744	-17,824	chief legal officer
Mar 14, 2024	green kevin dennis	sold	-42,443	1.9744	-21,497	chief financial officer
Mar 13, 2024	green kevin dennis	sold	-42,438	2.0153	-21,058	chief financial officer
Mar 13, 2024	greenman william mariner	sold	-128,182	2.057	-62,315	president and ceo
Mar 13, 2024	corash laurence m	sold	-28,935	2.057	-14,067	chief scientific officer
Mar 13, 2024	moore carol	sold	-41,552	2.01527	-20,619	svp reg. & quality

Which funds bought or sold CERS recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 23, 2024	AMALGAMATED BANK	reduced	-76.00	-43,000	11,000	-%
Apr 22, 2024	RAYMOND JAMES & ASSOCIATES	reduced	-12.9	-186,170	596,333	-%
Apr 22, 2024	MetLife Investment Management, LLC	unchanged	-	49,275	197,098	-%
Apr 19, 2024	Sumitomo Mitsui Trust Holdings, Inc.	added	2.41	-1,698,210	14,648,800	0.01%
Apr 18, 2024	WASATCH ADVISORS LP	reduced	-3.77	-2,227,880	11,877,000	0.06%
Apr 18, 2024	Capital Advisors, Ltd. LLC	unchanged	-	-	1,000	-%
Apr 18, 2024	ARK Investment Management LLC	added	3.02	-4,454,520	40,720,400	0.28%
Apr 18, 2024	Oak Thistle LLC	new	-	21,971	21,971	0.02%
Apr 17, 2024	Stephens Consulting, LLC	reduced	-0.51	-443	2,977	-%
Apr 16, 2024	Stratos Wealth Partners, LTD.	sold off	-100	-36,107	-	-%

Are Funds Buying or Selling CERS?

Are funds buying CERS calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CERS

No. of Funds

Unveiling Cerus Corp's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	baker bros. advisors lp	10.7%	19,477,339	SC 13G/A
Feb 13, 2024	vanguard group inc	5.45%	9,870,671	SC 13G/A
Jan 29, 2024	ark investment management llc	11.54%	20,914,326	SC 13G/A
Jan 26, 2024	blackrock inc.	7.6%	13,728,396	SC 13G/A
Nov 13, 2023	baker bros. advisors lp	10.5%	19,082,012	SC 13G/A
Feb 14, 2023	baker bros. advisors lp	9.1%	16,067,558	SC 13G/A
Feb 10, 2023	ark investment management llc	10.11%	17,943,131	SC 13G/A
Feb 10, 2023	ark investment management llc	8.94%	15,863,384	SC 13G/A
Feb 10, 2023	nikko asset management americas, inc.	4.04%	7,171,280	SC 13G/A
Feb 09, 2023	vanguard group inc	6.14%	10,900,422	SC 13G/A

Recent SEC filings of Cerus Corp

View All Filings

Date Filed	Form Type	Document
Mar 19, 2024	8-K	Current Report
Mar 14, 2024	4	Insider Trading
Mar 14, 2024	4	Insider Trading
Mar 14, 2024	4	Insider Trading
Mar 14, 2024	4	Insider Trading
Mar 14, 2024	4	Insider Trading
Mar 14, 2024	4	Insider Trading
Mar 14, 2024	4	Insider Trading
Mar 12, 2024	4	Insider Trading
Mar 08, 2024	144	Notice of Insider Sale Intent

Peers (Alternatives to Cerus Corp)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	186.7B	40.1B	-2.69%	-2.54%	32.62	4.65	-8.12%	-17.45%
BDX	67.7B	19.5B	-4.86%	-10.59%	53.89	3.47	4.02%	-22.04%
ALGN	23.4B	3.9B	-2.36%	-14.10%	52.63	6.06	3.42%	23.09%
BAX	20.8B	14.8B	-2.22%	-9.67%	7.84	1.41	2.12%	209.17%
MID-CAP
HSIC	9.4B	12.3B	-0.49%	-14.47%	22.48	0.76	-2.44%	-22.68%
ATR	9.3B	3.5B	-1.02%	16.40%	32.52	2.65	4.97%	18.89%
BIO	8.3B	2.7B	-18.63%	-38.25%	-13.07	3.12	-4.68%	82.43%
XRAY	6.4B	4.0B	-5.77%	-25.53%	-47.58	1.61	1.10%	85.84%
AXNX	3.4B	366.4M	-2.62%	10.65%	-558.61	9.25	33.86%	89.83%
PDCO	2.3B	6.6B	-4.73%	-4.84%	12.02	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	-11.22%	-19.13%	-1.92	0.41	7.73%	-1066.14%
ANIK	383.0M	166.7M	1.30%	-3.37%	-4.63	2.3	6.67%	-456.34%
ANGO	241.5M	324.0M	12.50%	-31.24%	-1.26	0.75	-3.19%	-337.41%
APYX	45.7M	52.3M	5.60%	-56.15%	-2.44	0.87	17.61%	19.28%
AEMD	4.0M	3.7M	-11.70%	184.91%	-0.32	1.06	5.77%	8.23%

Cerus Corp News

Latest updates

Cerus Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2018Q4	2018Q3	2018Q2	2018Q1	2017Q4
Revenue	-	-	-	-	-	-	112,524,000	18,549,000	16,161,000	12,284,000	79,506,000	12,654,000	11,798,000	10,291,000	64,168,000	10,436,000	10,098,000	51,195,000	7,257,000	7,700,000	13,564,000	16,240,000
Operating Expenses	-8.6%	31,557,000	34,538,000	41,853,000	38,935,000	41,774,000	37,575,000	35,645,000	36,841,000	34,918,000	35,752,000	32,220,000	31,730,000	31,723,000	33,602,000	32,221,000	31,157,000	27,254,000	24,789,000	24,318,000	23,044,000	-
S&GA Expenses	6.9%	17,269,000	16,155,000	20,541,000	21,551,000	23,160,000	22,003,000	20,357,000	19,758,000	19,170,000	18,691,000	16,299,000	16,112,000	15,913,000	17,164,000	16,140,000	16,740,000	14,833,000	13,964,000	14,437,000	13,607,000	-
EBITDA Margin	31.8%	-0.14	-0.21	-0.22	-0.20	-0.18	-0.29	-0.41	-0.44	-0.46	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expenses	-5.7%	2,229,000	2,364,000	2,181,000	1,612,000	1,697,000	1,334,000	1,279,000	1,338,000	972,000	952,000	930,000	929,000	935,000	960,000	1,031,000	1,150,000	1,082,000	1,053,000	958,000	915,000	-
Income Taxes	-7.7%	72,000	78,000	98,000	77,000	267,000	71,000	73,000	77,000	98,000	92,000	68,000	67,000	57,000	82,000	60,000	61,000	60,000	56,000	59,000	54,000	-
Earnings Before Taxes	81.7%	-1,317,000	-7,208,000	-13,233,000	-15,564,000	-13,358,000	-9,050,000	-12,364,000	-15,284,000	-17,359,000	-14,289,000	-14,071,000	-14,804,000	-16,409,000	-16,841,000	-17,907,000	-17,501,000	-16,145,000	-14,136,000	-13,223,000	-13,831,000	-
EBT Margin	23.8%	-0.20	-0.26	-0.27	-0.24	-0.22	-0.34	-0.47	-0.51	-0.52	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	82.3%	-1,289,000	-7,267,000	-13,331,000	-15,641,000	-13,621,000	-9,119,000	-12,437,000	-15,361,000	-17,457,000	-14,381,000	-14,139,000	-14,871,000	-16,466,000	-16,923,000	-17,967,000	-17,562,000	-16,205,000	-14,192,000	-13,282,000	-13,885,000	-
Net Income Margin	24.1%	-0.20	-0.26	-0.27	-0.25	-0.23	-0.34	-0.47	-0.51	-0.52	-	-	-	-	-	-	-	-	-	-	-	-
Free Cashflow	-15.6%	-15,177,000	-13,124,000	-9,440,000	-10,024,000	-2,991,000	-1,686,000	-6,803,000	-8,695,000	-17,648,000	-	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-3.9%	198	206	199	209	218	215	216	222	237	219	223	221	221	213	215	215	166	164	175	176	163
Current Assets	-4.3%	144	151	151	162	170	165	165	173	187	178	186	181	183	177	179	178	128	126	136	135	147
Cash Equivalents	-33.0%	12.00	17.00	21.00	28.00	36.00	31.00	34.00	40.00	51.00	81.00	61.00	60.00	39.00	31.00	37.00	36.00	37.00	27.00	26.00	32.00	32.00
Inventory	-6.5%	40.00	43.00	41.00	37.00	29.00	28.00	28.00	29.00	27.00	29.00	31.00	24.00	23.00	19.00	18.00	22.00	19.00	21.00	17.00	16.00	14.00
Net PPE	-6.6%	9.00	9.00	10.00	11.00	11.00	11.00	11.00	12.00	12.00	13.00	13.00	13.00	14.00	14.00	15.00	15.00	15.00	15.00	15.00	16.00	8.00
Goodwill	0%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Liabilities	-8.0%	144	157	147	150	150	141	140	141	152	138	139	128	118	104	101	103	108	104	109	106	79.00
Current Liabilities	-15.7%	68.00	80.00	75.00	78.00	117	95.00	79.00	67.00	79.00	65.00	66.00	55.00	60.00	46.00	43.00	45.00	50.00	46.00	51.00	48.00	53.00
Shareholder's Equity	9.3%	53.00	48.00	52.00	60.00	68.00	74.00	77.00	80.00	86.00	81.00	84.00	93.00	104	109	115	112	57.00	61.00	66.00	70.00	85.00
Retained Earnings	-0.1%	-1,044	-1,043	-1,036	-1,022	-1,007	-993	-985	-976	-964	-955	-942	-927	-909	-895	-881	-866	-850	-833	-815	-797	-778
Additional Paid-In Capital	0.4%	1,098	1,093	1,089	1,083	1,077	1,070	1,063	1,057	1,049	1,035	1,027	1,019	1,013	1,004	995	979	907	894	881	867	864
Shares Outstanding	0.7%	181	180	179	178	178	176	177	174	171	171	170	169	-	-	-	-	-	-	-	-	-
Minority Interest	-7.1%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	-	-	-	-	-	-	-	-	-	-	-
Float	-	-	-	373	-	-	-	906	-	-	-	862	-	-	-	928	-	-	-	771	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-44.8%	-15,183	-10,489	-8,996	-8,500	-1,756	-2,058	-345	-21,456	-1,222	-6,582	-8,663	-17,455	-8,901	-5,189	-7,919	-19,802	-8,222	-22,217	-12,882	-22,178	-7,095
Share Based Compensation	23.2%	4,903	3,979	5,720	5,669	7,255	5,768	5,007	6,426	6,538	5,892	5,808	5,333	4,723	4,846	4,706	3,754	3,700	3,595	3,139	2,878	2,815
Cashflow From Investing	3087.6%	8,216	-275	2,329	-1,646	7,383	-2,066	-5,475	8,622	-40,290	21,729	9,857	21,392	7,602	-5,380	-1,595	-50,185	9,401	10,028	-4,429	13,185	7,227
Cashflow From Financing	-84.4%	1,183	7,602	-173	2,061	457	1,084	202	2,449	12,098	4,581	127	17,488	8,287	4,171	10,641	68,684	9,484	13,066	11,804	9,133	6,399

CERS Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenue	$ 186,797	$ 188,315	$ 159,518
Operating expenses:
Research and development	67,639	64,107	63,691
Selling, general and administrative	75,516	83,335	81,288
Restructuring	3,728
Total operating expenses	146,883	147,442	144,979
Loss from operations	(30,053)	(34,081)	(48,936)
Non-operating expense, net:
Foreign exchange loss	(648)	(690)	(572)
Interest expense	(8,386)	(5,831)	(4,923)
Other income (expense), net	1,765	(1,735)	374
Total non-operating expense, net	(7,269)	(8,256)	(5,121)
Loss before income taxes	(37,322)	(42,337)	(54,057)
Provision for income taxes	325	488	319
Net loss	(37,647)	(42,825)	(54,376)
Net loss attributable to noncontrolling interest	(158)	(46)	(2)
Net loss attributable to Cerus Corporation	$ (37,489)	$ (42,779)	$ (54,374)
Net loss per share attributable to Cerus Corporation
Basic	$ (0.21)	$ (0.24)	$ (0.32)
Diluted	$ (0.21)	$ (0.24)	$ (0.32)
Weighted average shares outstanding:
Basic	180,270	176,545	171,279
Diluted	180,270	176,545	171,279
Product
Revenue	$ 156,367	$ 162,048	$ 130,859
Cost of revenue	69,967	74,954	63,475
Gross profit	86,400	87,094	67,384
Government Contract
Revenue	$ 30,430	$ 26,267	$ 28,659

CERS Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 11,647	$ 35,585
Short-term investments	54,205	66,569
Accounts receivable, net	35,500	34,426
Current inventories	39,868	29,003
Prepaid and other current assets	3,221	4,561
Total current assets	144,441	170,144
Non-current assets:
Property and equipment, net	8,640	10,969
Operating lease right-of-use assets	10,713	12,512
Goodwill	1,316	1,316
Restricted cash	1,712	1,773
Non-current inventories	19,501	15,494
Other assets	11,425	5,884
Total assets	197,748	218,092
Current liabilities:
Accounts payable	23,842	33,002
Accrued liabilities	19,225	25,203
Debt – current	20,000	56,159
Operating lease liabilities – current	2,452	2,105
Deferred revenue	2,002	589
Total current liabilities	67,521	117,058
Non-current liabilities:
Debt – non-current	59,796	13,644
Operating lease liabilities – non-current	13,751	15,329
Other non-current liabilities	3,236	3,499
Total liabilities	144,304	149,530
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.001 par value; 5,000 shares authorized, issuable in series; zero shares issued and outstanding at December 31, 2023 and 2022, respectively
Common stock, $0.001 par value; 400,000 and 400,000 shares authorized; 181,248 and 177,582 shares issued and outstanding at December 31, 2023 and 2022, respectively	181	177
Additional paid-in capital	1,098,353	1,077,341
Accumulated other comprehensive loss	(1,274)	(2,787)
Accumulated deficit	(1,044,610)	(1,007,121)
Total Cerus Corporation stockholders' equity	52,650	67,610
Noncontrolling interest	794	952
Total liabilities and stockholders' equity	$ 197,748	$ 218,092

About Cerus Corp

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.

CEO	Mr. William M. Greenman
WEBSITE	cerus.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	665

Cerus Corp Frequently Asked Questions

What is the ticker symbol for Cerus Corp? What does CERS stand for in stocks?

CERS is the stock ticker symbol of Cerus Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Cerus Corp (CERS)?

As of Tue Apr 23 2024, market cap of Cerus Corp is 304.55 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CERS stock?

You can check CERS's fair value in chart for subscribers.

What is the fair value of CERS stock?

You can check CERS's fair value in chart for subscribers. The fair value of Cerus Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Cerus Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CERS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Cerus Corp a good stock to buy?

The fair value guage provides a quick view whether CERS is over valued or under valued. Whether Cerus Corp is cheap or expensive depends on the assumptions which impact Cerus Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CERS.

What is Cerus Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 23 2024, CERS's PE ratio (Price to Earnings) is -8.12 and Price to Sales (PS) ratio is 1.63. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CERS PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Cerus Corp's stock?

In the past 10 years, Cerus Corp has provided -0.09 (multiply by 100 for percentage) rate of return.